Comparative Pharmacology
Head-to-head clinical analysis: LO LOESTRIN FE versus LO MALMOREDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LO LOESTRIN FE versus LO MALMOREDE.
LO LOESTRIN FE vs LO-MALMOREDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination of ethinyl estradiol and norethindrone acetate suppresses gonadotropin-releasing hormone (GnRH) from the hypothalamus, reducing luteinizing hormone (LH) and follicle-stimulating hormone (FSH) from the pituitary, thereby inhibiting ovulation. The progestin component thickens cervical mucus, impeding sperm penetration, and alters endometrial receptivity. Ferrous fumarate provides supplemental iron.
LO-MALMOREDE is a synthetic peptide analog of glucagon-like peptide-1 (GLP-1) that acts as a GLP-1 receptor agonist. It enhances glucose-dependent insulin secretion, suppresses glucagon release, slows gastric emptying, and promotes satiety by activating GLP-1 receptors in the pancreas, gastrointestinal tract, and central nervous system.
One tablet orally once daily. Each tablet contains norethindrone acetate 1 mg and ethinyl estradiol 10 mcg (24 active tablets) followed by ferrous fumarate 75 mg (2 inactive tablets).
Adults: 10 mg orally once daily, titrated to 20 mg once daily after 2 weeks if tolerated.
None Documented
None Documented
Norethindrone: ~8 hours (range 5–12 h); Ethinyl estradiol: ~14 hours (range 10–20 h). Terminal half-life supports once-daily dosing with steady-state reached within 7–14 days.
Terminal elimination half-life is approximately 4-6 hours; prolonged to 12-18 hours in moderate-to-severe renal impairment, requiring dose interval extension.
Renal (primarily as glucuronide conjugates of norethindrone and ethinyl estradiol): ~40% norethindrone metabolites, ~30% ethinyl estradiol metabolites; Fecal: ~30% norethindrone metabolites, ~40% ethinyl estradiol metabolites.
Primarily renal (75-90% unchanged); renal clearance approximates GFR, with dose adjustment needed for CrCl <30 mL/min. Biliary/fecal excretion accounts for <10%.
Category C
Category C
Combination Oral Contraceptive
Combination Oral Contraceptive